The company's stock has dropped by 1.58% in the past month, falling short of the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14%. Any recent changes to analyst estimates for Viking Therapeutics, Inc. should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 ...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2809, a novel, orally available, small molecule selective thyroi ...

Let's look beyond the hype the company is generating this year. Could 2024 be a breakout year for Viking Therapeutics (VKTX -4.01%)? The mid-cap biotech has generated more positive headlines than most of its peers. Excitement is through the roof. Due to crucial clinical progress, Viking Therapeutics' shares have tripled this year. Biotech investors have noticed, but many remain on the sidelines wondering whether Viking is the right choice for them -- or whether the stock is a one-hit (or one-year) wonder. L ...

Viking's stock has tripled in less than a year, and its red-hot valuation could have investors thinking twice about buying it today. It's not only Viking's share price that has been falling; volume is down, too Investors could still be waiting a long time for approval of a treatment Meanwhile, many top healthcare companies are developing weight loss drugs of their own to try to grab a piece of the lucrative anti-obesity market, which could grow to be worth $100 billion by 2030, according to estimates from G ...

Sasha Brazhnik/iStock via Getty Images +3.02 (5.93%) 100.00 90.00 80.00 70.00 60.00 40.00 54.03 50.00 30.00 10.00 Jul The weight loss drug sector is seeing an incecasingly intensified drug development focus, causing a small player like Viking Therapeuties, Inc. (NASDAQ:VKTX) to The wegen world, broken in metelings meaning due, est lest, but the fear is not one mail pay than your man partier for O.P-1 man arte norse. slip. The small biotech has has Potentially Crowded Market VIKING Goldman Sachs has jumped M ...

Viking Therapeutics (VKTX) has been attracting investor interest for quite a while, all thanks to the rapid progress of its pipeline candidates targeting obesity and non-alcoholic steatohepatitis (NASH) indications. This year, management reported encouraging results on its obesity and NASH drug programs. These results position the company's pipeline candidates strongly against currently available therapies targeting these diseases. So far this year, the stock has surged 197.3% against the industry's 6.3% de ...

It's a tough act to follow. Few biotech companies have made more noise than Viking Therapeutics (VKTX 4.41%) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the industry. However, Viking's prominence and stock price soared thanks to excellent clinical progress. The biotech's shares are up by 154% since early January. Why Viking Therapeutics has been on fire Among this herd of drugmakers -- outside of Eli Lilly and Novo Nordisk -- Viking Therapeutics ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other juris ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 EarninConference Call April 24, 2024 8:30 AM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Joon Lee - Truist Kambiz Yazdi - Jefferies Annabel Samimy - Stifel Jay Olson - Oppenheimer Andrew Hsieh - William Blair Nick Econom - Raymond James Thomas Smith - Leerink Partners Yale Jen - Laidlaw & Co Justin Zelin - BTIG Operator ...

Exhibit 99.1 Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, April 24, 2024 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical pipeline and other corpo ...